Loading...
Loading...
VBIV| Name | Value |
|---|---|
| Revenues | 6.6M |
| Cost of Revenue | 2.5M |
| Gross Profit | 4.1M |
| Operating Expense | 14.2M |
| Operating I/L | -10.1M |
| Other Income/Expense | -10.4M |
| Interest Income | 0.5M |
| Pretax | -20.4M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -20.4M |
VBI Vaccines Inc. is a biopharmaceutical company specializing in the development and sale of vaccines for infectious diseases and immuno-oncology. The company's primary product, Sci-B-Vac, is a prophylactic hepatitis B (HBV) vaccine. Additionally, VBI-2601 (BRII-179) is being developed as an immunotherapeutic candidate for chronic HBV infection. Using its enveloped virus-like particle (eVLP) platform technology, VBI Vaccines Inc. creates eVLP vaccines that mimic virus presentation to elicit the human immune system. The company's lead eVLP program candidates include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical study, and VBI-1501, a prophylactic cytomegalovirus vaccine that has completed Phase I clinical trial.
